Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1/2 1

Status

Active not recruiting 69Recruiting 39Completed 17Not yet recruiting 7Terminated 4Withdrawn 2Suspended 2

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 5Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 3Lymphoma, Follicular 2Neoplasms, Plasma Cell 1Malignant Plasma Cell Neoplasms 1Leukemia, Plasma Cell 1

Interventions

Specimen Handling 62Magnetic Resonance Spectroscopy 44Cyclophosphamide 32Gemcitabine 29Carboplatin 27Biopsy 26pembrolizumab 23Radiotherapy 23Bevacizumab 23Paclitaxel 22venetoclax 21fludarabine 21Nivolumab 21Cisplatin 21Standard of Care 20Drug Therapy 20Capecitabine 20Oxaliplatin 19Radiosurgery 16Blood Specimen Collection 16Azacitidine 16Interviews as Topic 15Dexamethasone 15toripalimab 14cemiplimab 14Docetaxel 14tislelizumab 13Injections 13anlotinib 11Fluorouracil 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Not yet recruiting × Lenalidomide × 90 days × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT07600151 2026-05-20

CONQUISTADOR

Universitätsklinikum Hamburg-Eppendorf

Phase 1/2 Not yet recruiting
220 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07285239 2026-05-18

PrE1005

PrECOG, LLC.

Phase 3 Not yet recruiting
500 enrolled
Plasma cell

Multiple Myeloma

NCT07585747 2026-05-14

CUREMZL002

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
27 enrolled
Lymphoid

Lymphoma, Follicular

NCT07560449 2026-05-01

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

Qilu Pharmaceutical Co., Ltd.

Phase 2 Not yet recruiting
162 enrolled
Plasma cell

Malignant Plasma Cell Neoplasms

NCT07562022 2026-05-01

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Sinocelltech Ltd.

Phase 3 Not yet recruiting
93 enrolled
Lymphoid

Lymphoma, Follicular

NCT07485647 2026-03-20

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

Vanderbilt-Ingram Cancer Center

Phase 2 Not yet recruiting
50 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡